Invasive fungal infections diagnosed during the study period
Infection . | Fluconazole . | Itraconazole . |
|---|---|---|
| Invasive mold infections (%)* | 23 (16) | 23 (15) |
| Proven | 9 (6) | 11 (7) |
| Probable | 11 (7) | 5 (3) |
| Possible | 3 (2) | 7 (5) |
| Candidemia (%) | 5 (3) | 4 (3) |
Infection . | Fluconazole . | Itraconazole . |
|---|---|---|
| Invasive mold infections (%)* | 23 (16) | 23 (15) |
| Proven | 9 (6) | 11 (7) |
| Probable | 11 (7) | 5 (3) |
| Possible | 3 (2) | 7 (5) |
| Candidemia (%) | 5 (3) | 4 (3) |
Proven, probable, or possible infections were defined according to standardized criteria.13 Total percentages were calculated from 148 evaluable patients in the fluconazole arm and 151 patients in the itraconazole arm. One patient in the itraconazole arm developed both candidemia and probable invasive mold infection.